TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16369129

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 1 x 300 or 480 microg s.c. prior to standard antibiotic treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard treatment only (control group)
Number of subjects: 16
Study: 15151666

Group type: EXPERIMENTAL
Intervention: White wine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (baseline measurement)
Number of subjects: 14
Study: 11168137

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 178

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 178
Study: 9120927

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 556
Study: 7920884

Group type: EXPERIMENTAL
Intervention: Patients with chronic thyroiditis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study: 3539615

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 0
Study: 31987684

Group type: EXPERIMENTAL
Intervention: Preoperative education on mechanical ventilation and communication panel usage
Number of subjects: 200

Group type: COMPARATOR
Intervention: No education
Number of subjects: 200
Study: 29538636

Group type: EXPERIMENTAL
Intervention: Immediate ART with Efavirenz (EFV)
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Immediate ART with other prespecified regimens
Number of subjects: 4684

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4684
Study: 27421759

Group type: EXPERIMENTAL
Intervention: Interactive tailored informational messages about sustainable healthy eating delivered via a mobile smartphone app
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative longitudinal research to explore openness to adopting sustainable healthy eating behaviour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative research to develop a sustainable healthy eating behaviour index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised controlled trial
Number of subjects: 0
Study: 23445173

Group type: EXPERIMENTAL
Intervention: 2BOD (ball attachment on two implants)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2ROD (bar attachment on two implants)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 4ROD (bar attachments on four implants)
Number of subjects: 18

Group type: COMPARATOR
Intervention: CD (control, conventional dentures)
Number of subjects: 18
Study: 23328326

Group type: EXPERIMENTAL
Intervention: Hypnosis (hypnotic analgesia suggestions)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (relaxation)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Baseline somatosensory sensitivity
Number of subjects: 41
Study: 20492050

Group type: EXPERIMENTAL
Intervention: Preferred music listening intervention (30-minute sessions, twice a week for six weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual standard care with no music
Number of subjects: 52
Study: 17691577

Group type: EXPERIMENTAL
Intervention: Otopoint-penetrative needling
Number of subjects: 98

Group type: COMPARATOR
Intervention: Otopoint-straight needling
Number of subjects: 98
Study: 15186869

Group type: EXPERIMENTAL
Intervention: Adaptive computer-based hypoglycaemia education program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional computer-based hypoglycaemia education program
Number of subjects: 120
Study: 11480943

Group type: EXPERIMENTAL
Intervention: Psychosocial support and basic medical care (n = 42)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Medical care only (n = 45)
Number of subjects: 87
Study: 9751091

Group type: EXPERIMENTAL
Intervention: SC-58635
Number of subjects: 0

Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 0

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 0
Study: 8150115

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRH‐a) discontinued as gonadotropin stimulation began
Number of subjects: 173

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (GnRH‐a) continued as gonadotropin stimulation began
Number of subjects: 173
Study: 3258170

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 22
Study: 31446416

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led behavioural change intervention (MOSAIC)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 192
Study: 29876530

Group type: EXPERIMENTAL
Intervention: (Pyr(1))apelin‐13 infusion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: (Pyr(1))apelin‐13 infusion with concomitant phosphodiesterase type 5 inhibition
Number of subjects: 19

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 19
Study: 27178989

Group type: EXPERIMENTAL
Intervention: RemoweLL cardiotomy reservoir
Number of subjects: 45

Group type: COMPARATOR
Intervention: Admiral cardiotomy reservoir
Number of subjects: 45
Study: 25160890

Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social- and computer-contact control group
Number of subjects: 0
Study: 22982658

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg orally twice daily for 2 months)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 299
Study: 20012601

Group type: EXPERIMENTAL
Intervention: Oral lovastatin (20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (verapamil 60 mg without lovastatin)
Number of subjects: 14
Study: 17413685

Group type: EXPERIMENTAL
Intervention: TMC114/ritonavir (TMC114/r)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control PI drug(s) (CPI)
Number of subjects: 278
Study: 16319551

Group type: EXPERIMENTAL
Intervention: Red grape polyphenol extract (600 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (20 ml of water)
Number of subjects: 30
Study: 12435182

Group type: EXPERIMENTAL
Intervention: Closed cooled-tip catheter
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 8-mm-tip catheter
Number of subjects: 100
Study: 10492627

Group type: EXPERIMENTAL
Intervention: FAMTX (5-fluorouracil, doxorubicin, methotrexate) before surgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 56
Study: 8568486

Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (25 units, MSD) at 0, 24 weeks (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (25 units, MSD) at 0, 2, 24 weeks (group II)
Number of subjects: 60
Study: 2007359

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms four times daily
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Misoprostol 300 micrograms four times daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Higher density of H. pylori
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Degree of gastritis
Number of subjects: 147
Study: 6284190

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 0.15 g/m2
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 0.30 g/m2
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 0.45 g/m2
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO)
Number of subjects: 48
Study: 30611292

Group type: EXPERIMENTAL
Intervention: M4bH and IAQ feedback
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: M4bH alone
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Usual services only
Number of subjects: 1800
Study: 28111429

Group type: EXPERIMENTAL
Intervention: Necitumumab plus gemcitabine and cisplatin (neci+GC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin (GC)
Number of subjects: 84
Study: 23743219

Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 52
Study: 23406936

Group type: COMPARATOR
Intervention: Mometasone furoate delivered by dry powder inhaler (MF-DPI) 100 microgram q.d. P.M.
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Mometasone furoate delivered by dry powder inhaler (MF-DPI) 200 microgram q.d. P.M.
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Mometasone furoate delivered by dry powder inhaler (MF-DPI) 100 microgram
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Mometasone furoate delivered by dry powder inhaler (MF-DPI) 200 microgram
Number of subjects: 1445
Study: 21543375

Group type: EXPERIMENTAL
Intervention: Low 25-hydroxy-vitamin D (25(OH)D) levels
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Low 25-hydroxy-vitamin D (25(OH)D) concentration
Number of subjects: 548
Study: 19084440

Group type: EXPERIMENTAL
Intervention: Topiramate (4 RCTs, 2 uncontrolled trials)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Sodium valproate/divalproex sodium (2 RCTs, 1 uncontrolled trial, 2 retrospective chart reviews)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Levetiracetam (only uncontrolled studies)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Zonisamide (only uncontrolled studies)
Number of subjects: 939
Study: 17561515

Group type: EXPERIMENTAL
Intervention: Epidural naloxone with sufentanil in ropivacaine (Group N)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sufentanil in ropivacaine alone (Group C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (Group N and Group C)
Number of subjects: 50
Study: 15220654

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unifil Bond
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ABF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (positive and negative controls)
Number of subjects: 40
Study: 11487656

Group type: EXPERIMENTAL
Intervention: Listening to music (musicians)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Listening to music (non-musicians)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting conditions (musicians)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting conditions (non-musicians)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Listening to neutral text (musicians)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Listening to neutral text (non-musicians)
Number of subjects: 0
Study: 9728827

Group type: EXPERIMENTAL
Intervention: Ciaglia method (gradual dilation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Portex method (single dilation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 80
Study: 8906943

Group type: EXPERIMENTAL
Intervention: Nimodipine (1.5 to 2.0 mg/kg/day) administered orally or as continuous intravenous drip for the first three days followed by oral therapy along with standard treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical care (BMC) for ICVD control cases.
Number of subjects: 0
Study: 2319049

Group type: EXPERIMENTAL
Intervention: Nicotine gum (delivered ad lib or on a fixed regimen)
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 1218

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Self-guided behavioral treatment (self-selected modules, randomly administered modules, no modules)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Nicotine gum (for men)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Nicotine gum (for women)
Number of subjects: 1218
Study: 508553

Group type: EXPERIMENTAL
Intervention: Intravenous administration of metoclopramide (5 and 10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of metoclopramide (aqueous solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of metoclopramide (slow release tablet)
Number of subjects: 0
Study: 31679512

Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education program (six sessions, 10 h) and group physical exercise (18 sessions program carried out in six weeks, 18 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care physiotherapy treatment
Number of subjects: 0
Study: 28716153

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 1000
Study: 26375804

Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Building Blocks (BB)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control
Number of subjects: 438
Study: 24135054

Group type: EXPERIMENTAL
Intervention: Active rTMS and venlafaxine
Number of subjects: 540

Group type: COMPARATOR
Intervention: Sham rTMS and venlafaxine
Number of subjects: 540

Group type: COMPARATOR
Intervention: Venlafaxine alone
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 540
Study: 20126968

Group type: EXPERIMENTAL
Intervention: HEPA programme (8-week health enhancing and physical activity programme)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study: 18945396

Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 3178

Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment (SSRIs)
Number of subjects: 3178

Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment (other antidepressants)
Number of subjects: 3178

Group type: COMPARATOR
Intervention: Pharmacologic treatment
Number of subjects: 3178
Study: 16628714

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lenograstim
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (blood donors)
Number of subjects: 20
Study: 14650863

Group type: EXPERIMENTAL
Intervention: Fondaparinux for prevention of VTE in orthopedic surgical patients (PENTHIFRA Plus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux for prevention of VTE in high-risk abdominal surgical patients (PEGASUS and APOLLO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux for prevention of VTE in medical patients (ARTEMIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux for treatment of VTE (MATISSE DVT and MATISSE PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux for treatment of acute coronary syndromes (PENTALYSE and PENTUA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux in orthopedic prophylactic and nonorthopedic clinical programs
Number of subjects: 0
Study: 10818057

Group type: EXPERIMENTAL
Intervention: Active treatment (chlorthalidone-based treatment)
Number of subjects: 4126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4126

Group type: EXPERIMENTAL
Intervention: Active treatment with hypokalemia
Number of subjects: 4126

Group type: EXPERIMENTAL
Intervention: Active treatment with normal potassium levels
Number of subjects: 4126
Study: 8788488

Group type: EXPERIMENTAL
Intervention: N,N-dimethyltryptamine (DMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pindolol pre-treatment
Number of subjects: 0
Study: 1521944

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg/24 h)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6442971

Group type: EXPERIMENTAL
Intervention: BCG and 5‐fluorouracil alone (regimen A)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: BCG and 5‐fluorouracil in combination with hydroxyurea, methyl‐CCNU and mitomycin C (regimen B)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cox method for linear regression analysis on non‐parametric data
Number of subjects: 168
Study: 29603657

Group type: EXPERIMENTAL
Intervention: Low-Glycemic Index (LGI) diet
Number of subjects: 122
Study: 29484469

Group type: EXPERIMENTAL
Intervention: 8-day antibiotic therapy
Number of subjects: 410

Group type: COMPARATOR
Intervention: 15-day antibiotic therapy
Number of subjects: 410
Study: 27491220

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture (performed during the operation from specific acupuncture points)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no scalp acupuncture)
Number of subjects: 84
Study: 24524697

Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) meal (glycemic index = 37)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mixed meal (CON; glycemic index ∼57)
Number of subjects: 12
Study: 22922781

Group type: EXPERIMENTAL
Intervention: Treatment for symptomatic convergence insufficiency
Number of subjects: 221
Study: 20877732

Group type: EXPERIMENTAL
Intervention: Twin blocks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flat occlusal splints
Number of subjects: 20
Study: 17549327

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural training programme
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Physical activity programme
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study: 17532965

Group type: EXPERIMENTAL
Intervention: Exogenous surfactant instillation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no surfactant instillation)
Number of subjects: 29
Study: 15354376

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St. John's Wort)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-adenosyl-methionine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-Hydroxytryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11432682

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g) as a single intravenous dose at anesthetic induction
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cefazolin (1 g) plus clindamycin (0.6 g) administered intravenously at anesthetic induction and for two more doses at 8‐hourly intervals for a total of 3 days
Number of subjects: 103
Study: 9355946

Group type: EXPERIMENTAL
Intervention: High-energy shockwave lithotripsy (Shock Tube C)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Low-energy shockwave lithotripsy (Siemens Lithostar)
Number of subjects: 336
Study: 8407423

Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single agent cisplatin and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-5-FU and split course radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2439827

Group type: EXPERIMENTAL
Intervention: bopindolol (1-2 mg daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: atenolol (50-100 mg daily)
Number of subjects: 33
Study: 30608598

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using gemcitabine and S-1
Number of subjects: 360

Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 360
Study: 28964662

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT-4) replacement therapy for 2 months
Number of subjects: 40
Study: 27510524

Group type: EXPERIMENTAL
Intervention: 6-week interval after chemoradiotherapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: 12-week interval after chemoradiotherapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (6-week and 12-week)
Number of subjects: 31
Study: 23815764

Group type: EXPERIMENTAL
Intervention: WCA history (67.5% of participants)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: WCA
Number of subjects: 114

Group type: COMPARATOR
Intervention: no-WCA
Number of subjects: 114
Study: 23195006

Group type: EXPERIMENTAL
Intervention: CNI-free maintenance therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low-dose CNI therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Glomerular filtration rates (GFR)
Number of subjects: 75
Study: 19200421

Group type: EXPERIMENTAL
Intervention: Lamotrigine (titrated to 200 mg/d)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 124
Study: 17550365

Group type: EXPERIMENTAL
Intervention: Math instruction group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard psychoeducational care group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Parental instruction workshops
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Achenbach Child Behavior Checklist
Number of subjects: 61
Study: 15376805

Group type: EXPERIMENTAL
Intervention: Probability-learning phase preceding reasoning tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard conditional inferences, card choices in the Wason selection task, and quantifiers from syllogisms
Number of subjects: 0
Study: 11289345

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (200 mg/day)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 9530599

Group type: EXPERIMENTAL
Intervention: Irrigating solution with heparin-sodium (10 IU/mL)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Regular irrigating solution (control)
Number of subjects: 72
Study: 7799578

Group type: EXPERIMENTAL
Intervention: Dressings containing a layer of aerosil 2-3 mm thick
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3240892

Group type: EXPERIMENTAL
Intervention: Gynatren
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 30913208

Group type: EXPERIMENTAL
Intervention: Fish oil (4g/d)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Aspirin (100mg/d)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo (for both fish oil and aspirin)
Number of subjects: 567
Study: 29130716

Group type: EXPERIMENTAL
Intervention: Processed quinoa (Kuska Active product)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30